Ypsomed

Historical price data

Ypsomed is a leading, revenue-generating Swiss developer and manufacturer of drug delivery systems, with a market cap of $3.73B. Its strategy is built on a modular platform approach, offering pen injectors, autoinjectors, and wearable injectors to pharmaceutical partners, thereby accelerating their drug development and commercialization. The company is a critical enabler in the rapidly expanding market for subcutaneous biologics, including GLP-1 agonists and monoclonal antibodies. Ypsomed's integrated services and digital health solutions further solidify its position as a full-service partner in patient self-care.

Industrialized, modular platform for self-injection systems, including pen injectors, autoinjectors, and wearable patch injectors, integrated with digital health solutions.

Ypsomed competes with global players like Gerresheimer, Schott Pharma, West Pharmaceutical Services, and BD. Its advantages include pure-play focus, an end-to-end partner model, Swiss engineering quality, and an industrialized platform strategy that offers speed and cost efficiency.